Polypill Programs to Prevent Stroke and Cut Costs in Low Income Countries: Moving From Clinical Efficacy to Pragmatic Implementation
Stroke · 2023
DOI: 10.1161/strokeaha.122.039567 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Stroke, 2023. Verfasst von Fred Stephen Sarfo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana (F.S.S.). Hauptthemen laut MEDLINE: Cardiovascular Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke, Atherosclerosis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NINDS NIH HHS.
Themen: Schlaganfall
Abstract (Originalsprache)
Current projections are that the already overwhelming burden of strokes and atherosclerotic cardiovascular diseases in low- and middle-income countries (LMICs) will continue to rise over the coming decades as the prevalence of traditional vascular risk factors burgeon in these countries. Cardiovascular polypills containing combinations of antihypertensive(s), a statin, with or without aspirin or folic acid in the form of a single pill, represent a viable strategy for both primary and secondary prevention of atherosclerotic cardiovascular diseases in LMICs. Large multicenter trials in LMIC and high-income country (HIC) settings have now clearly demonstrated the beneficial effects of the cardiovascular polypill versus placebo (or usual care) in reducing primary stroke risk by 50%. For survivors of a recent myocardial infarction residing in HICs, the polypill reduced risk of major cardiovascular events by 25% due to improved treatment adherence. Data on the clinical efficacy of the polypill for secondary stroke prevention are scanty both in HICs and LMICs. Cost-effectiveness analyses data from LMICs suggest cost savings with the polypill for primary and secondary prevention of stroke and atherosclerotic cardiovascular diseases. However, major contextual barriers in LMICs need to be surmounted through mixed methods research and hybrid clinical trials to assess its real-world effectiveness, before the adoption of the polypill for primary and secondary atherosclerotic cardiovascular disease prevention in routine clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Kwame Nkrumah University of Science & Technology, Kumasi, Ghana (F.S.S.).
- Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana (F.S.S., P.A.O.-A.).
- Department of Nursing, Medical University of South Carolina, Charleston (M.N.).
- Department of Neurology, University of California, San Francisco (B.O.).
ORCID-Profile: Fred Stephen Sarfo, Michelle Nichols, Priscilla Abrafi Opare-Addo, Bruce Ovbiagele
Förderung
- NHLBI NIH HHS
- NINDS NIH HHS
Zitieren
APA
Sarfo, F. S., Nichols, M., Opare-Addo, P. A., & Ovbiagele, B. (2023). Polypill Programs to Prevent Stroke and Cut Costs in Low Income Countries: Moving From Clinical Efficacy to Pragmatic Implementation. Stroke. https://doi.org/10.1161/strokeaha.122.039567
Vancouver
Sarfo FS, Nichols M, Opare-Addo PA, Ovbiagele B. Polypill Programs to Prevent Stroke and Cut Costs in Low Income Countries: Moving From Clinical Efficacy to Pragmatic Implementation. Stroke. 2023. doi:10.1161/strokeaha.122.039567
BibTeX
@article{Sarfo2023,
author = {Sarfo, Fred Stephen and Nichols, Michelle and Opare-Addo, Priscilla Abrafi and Ovbiagele, Bruce},
title = {Polypill Programs to Prevent Stroke and Cut Costs in Low Income Countries: Moving From Clinical Efficacy to Pragmatic Implementation},
journal = {Stroke},
year = {2023},
doi = {10.1161/strokeaha.122.039567}
}
EUVIMED